Skip to main content

Table 3 Univariate analysis of disease-free and overall survival

From: Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study

Disease-free survival

  
 

Oesophageal/GOJ adenocarcinoma

Gastric adenocarcinoma

Covariate

N

Median DFS (months, 95 % CI)

Hazard ratio (95 % CI)

P -value

N

Median DFS (months, 95 % CI)

Hazard ratio (95 % CI)

P -value

Elevated tumour markers

        

  No

24

12.2 (8.8–16.2)

1.0

0.794

16

10.8 (5.0–13.7)

1.0

0.081

  Yes

63

11.8 (8.4–13.6)

1.07 (0.66–1.72)

24

15.0 (10.6–24.8)

0.56 (0.29–1.08)

Differentiation

        

  Poor

107

12.3 (8.8–20.7)

1.0

<0.001

94

37.9 (21.5–71.8)

1.0

0.020

  Moderate/well

92

85.9 (33.1 – NA)

0.40 (0.27–0.58)

47

99.2 (36.2 – NA)

0.54 (0.32–0.91)

Pathological T-stage

        

  T0-2

112

111.7 (77.7 – NA)

1.0

<0.001

107

86.9 (51.4–99.6)

1.0

0.010

  T3/4

97

12.2 (8.7–18.0)

2.89 (2.00–4.18)

36

21.5 (12.7–40.5)

1.91 (1.16–3.12)

Pathological N-stage

        

  N0

105

111.7 (77.7 – NA)

1.0

<0.001

72

87.1 (86.9 – NA)

1.0

<0.001

  N1-3

105

11.8 (8.4–15.7)

3.38 (2.32–4.94)

71

21.1 (12.7 - 38.0)

3.10 (1.89–5.10)

Resection margin

        

  R0

161

77.7 (26.1 – NA)

1.0

<0.001

135

71.8 (35.6–99.6)

1.0

0.080

  R1/R2

47

8.7 (7.0–14.8)

2.87 (1.96–4.20)

7

13.2 (0.3 – NA)

2.13 (0.91–4.98)

Presence of symptoms at time of relapse

        

  No

33

10.9 (7.9–14.8)

1.0

0.793

13

11.5 (4.8–21.5)

1.0

0.259

  Yes

67

11.8 (7.2–12.4)

1.06 (0.70–1.61)

34

13.2 (8.1–20.6)

0.68 (0.35–1.32)

Neoadjuvant, adjuvant or perioperative therapy

        

  No

33

140.0 (111.7 – NA)

1.0

0.001

53

34.1 (13.1–87.1)

1.0

0.100

  Yes

181

20.9 (14.3–27.2)

3.57 (1.74–7.31)

 

93

86.9 (41.7 – NA)

0.67 (0.42–1.08)

Overall survival

  
 

Oesophageal/GOJ adenocarcinoma

Gastric adenocarcinoma

  Covariate

N

Median OS (months, 95 % CI)

Hazard ratio (95 % CI)

P -value

N

Median OS (months, 95 % CI)

Hazard ratio (95 % CI)

P -value

Elevated tumour markers

        

  No

24

28.8 (15.2–40.7)

1.0

0.343

16

20.0 (9.6–29.1)

1.0

0.842

  Yes

63

22.4 (14.9–31.5)

1.28 (0.77–2.11)

24

22.6 (15.9–34.4)

0.91 (0.49–1.80)

Differentiation

        

  Poor

107

21.5 (15.2–33.0)

1.0

<0.001

94

40.5 (28.5–86.9)

1.0

0.011

  Moderate/well

92

85.9 (76.7 – NA)

0.37 (0.25–0.55)

47

99.2 (53.7 – NA)

0.50 (0.29–0.85)

Pathological T-stage

        

  T0-2

112

111.7 (77.7 – NA)

1.0

<0.001

107

81.2 (53.9–99.6)

1.0

0.002

  T3/4

99

27.9 (14.9–35.2)

2.96 (2.00–4.36)

36

29.1 (17.2–40.5)

2.19 (1.33–3.61)

Pathological N-stage

        

  N0

105

111.7 (77.7 – NA)

1.0

<0.001

72

87.1 (86.9 – NA)

1.0

<0.001

  N1-3

105

25.1 (14.7–34.1)

3.33 (2.23–4.97)

71

28.5 (19.4–48.7)

3.16 (1.90–5.26)

Resection margin

        

  R0

161

77.7 (51.9 - NA)

1.0

<0.001

135

81.2 (48.8–99.6)

1.0

0.062

  R1/R2

47

13.8 (8.6–36.1)

2.83 (1.91–4.19)

7

17.2 (0.3 - NA)

2.25 (0.96–5.26)

Type of relapse

        

  None

114

140.0 (111.7 – NA)

1.0

(<0.001)

99

99.2 (63.9–110.5)

1.0

(<0.001)

  Local

5

38.1 (23.8 – NA)

3.72 (1.43–9.67)

0.007

4

20.0 (17.2 - NA)

5.61 (1.93–16.2)

0.001

  Distant

79

19.4 (14.4–27.9)

6.66 (4.25–10.4)

<0.001

37

20.9 (15.4–28.5)

7.13 (4.17–12.2)

<0.001

  Both

14

26.3 (12.5 – NA)

5.31 (2.55–11.1)

<0.001

6

23.1 (14.0 – NA)

5.88 (2.39–14.5)

<0.001

Presence of symptoms at time of relapse

        

  No

33

26.3 (22.1–38.9)

1.0

0.071

13

29.1 (15.4–53.7)

1.0

0.137

  Yes

66

18.6 (13.2–28.4)

1.52 (0.96–2.41)

34

20.0 (14.7–26.9)

1.68 (0.85–3.36)

Neoadjuvant, adjuvant or perioperative therapy

        

  No

33

140 (111.7 – NA)

1.0

0.006

53

34.4 (18.7–87.1)

1.0

0.028

  Yes

181

39.8 (28.8–59.6)

2.59 (1.31–5.14)

93

86.9 (53.6 – NA)

0.59 (0.37–0.94)

  1. NA means confidence interval is un-obtainable